#ClimateChange #Penguins #Biodiversity
www.yahoo.com
Researchers find Antarctic penguin breeding is heating up sooner, and that's a problem
WASHINGTON (AP) -- Warming temperatures are forcing Antarctic penguins to breed earlier and that's a big problem for two of the cute tuxedoed species that face extinction by the end of the century, a study said.
#Biotechnology #Epilepsy #ConferenceCall
www.benzinga.com
Bright Minds to Announce Topline Results for BMB-101 Phase 2 Trial in Absence Seizures and Developmental and Epileptic Encephalopathies on Tuesday, January 6, 2026 - Bright Minds Biosciences (NASDAQ:DRUG)
- Conference Call and Live Webcast at 8AM ET -
NEW YORK, Jan.
#Pelthos #Xeglyze #Biopharmaceuticals
www.benzinga.com
Pelthos Therapeutics Acquires Xeglyze® (abametapir) Topical Treatment for Head Lice - Pelthos Therapeutics (AMEX:PTHS)
Acquisition adds complementary asset to the Pelthos commercial portfolioXeglyze is a novel, FDA-approved prescription medication indicated for the topical treatment of head lice infestation in patients 6 months of age and older
DURHAM, N.
#Osteoporosis #Biotech #ClinicalTrials
www.benzinga.com
Angitia Biopharmaceuticals Completes Enrollment of Phase 2 ARTEMIS Trial Evaluating AGA2118 for the Treatment of Osteoporosis
Enter your email to get Benzinga's ultimate morning update: The PreMarket Activity Newsletter
- Company expects topline data from the study in 2027
WESTLAKE VILLAGE, Calif.
#Biopharma #Neuroscience #ClinicalTrials
www.benzinga.com
Neumora Therapeutics Highlights 2026 Pipeline Strategy and Anticipated Upcoming Milestones - Neumora Therapeutics (NASDAQ:NMRA)
Multiple clinical data readouts expected in 2026 present opportunity for substantial value creation
KOASTAL-2 and -3 on track for consolidated topline readout in the second quarter of 2026
Plans to conduct NMRA-215 clinical program in 2026 following class-leading preclinical data from diet induced obesity model
Advancing NMRA-511 following Phase 1b results demonstrating clinically meaningful effect on CMAI total score
Cash, cash equivalents and marketable securities expected to support operations into the third quarter of 2027
WATERTOWN, Mass.
#HealthTech #SmartScale #Biomarkers
www.macrumors.com
CES 2026: Withings Unveils Body Scan 2 With Hypertension Detection
Withings has announced the Body Scan 2, a new smart scale that the French health tech company says can track over 60 longitudinal biomarker measurements that enable the early detection of health issues and can even predict longevity.
